As of November 6, 2026, Sinovac Biotech Ltd. is a publicly traded company (Nasdaq: SVA). The largest holder reporting an active stake on Schedule 13D is 1Globe Capital LLC, at 32.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Yin Weidong, the chief executive and a director (8.85%) (Schedule 13D/A, September 12, 2025).
Is this your company?
About to sign with, pay or invest in Sinovac Biotech Ltd.? See the free Snapshot first.
Free to see. No signup.
Is Sinovac Biotech Ltd. a real, registered company?
- Sinovac Biotech LTD. files with the SEC under CIK 1084201 (its SEC filings).
- Its shares are listed under the ticker SVA on Nasdaq (SEC company record).
- Incorporated in B9, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SINOVAC BIOTECH LTD. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names SAIF Partners IV L.P. (filed 2025-12-17).
Who are Sinovac Biotech Ltd.'s owners and officers?
Sinovac Biotech Ltd.: industry Pharmaceutical Preparations (Schedule 13D/A, 2025-12-17).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2025-12-17 | Saif Partners Iv L.P. | 15% |
| Schedule 13D/A, 2025-09-12 | 1globe Capital LLC | 32.3% |
| Schedule 13D/A, 2025-07-15 | Weidong Yin | 8.85% |
| Schedule 13D/A, 2025-07-14 | Advantech Capital L.P. | 8.14% |
| Schedule 13D/A, 2025-07-14 | Saif Partners Iv L.P. | 15% |
| Schedule 13D/A, 2025-07-11 | Vivo Capital Viii, LLC | 6.3% |
| Schedule 13D/A, 2025-07-07 | 1globe Capital LLC | 32.3% |
| Schedule 13D/A, 2025-07-03 | 1globe Capital LLC | 32.3% |
| Schedule 13D/A, 2025-07-01 | 1globe Capital LLC | 32.3% |
Questions about who owns Sinovac Biotech Ltd.
Who owns Sinovac Biotech Ltd.?
On this page, 5 holders' latest ownership filings report 5% or more of Sinovac Biotech Ltd.: 1globe Capital LLC (32.3%, Schedule 13D/A, filed 2025-09-12), Saif Partners Iv L.P. (15%, Schedule 13D/A, filed 2025-12-17), Weidong Yin (8.85%, Schedule 13D/A, filed 2025-07-15), Advantech Capital L.P. (8.14%, Schedule 13D/A, filed 2025-07-14) and Vivo Capital Viii, LLC (6.3%, Schedule 13D/A, filed 2025-07-11).
Who are the largest shareholders of Sinovac Biotech Ltd.?
By the share each holder's latest filing reports, the largest holders of Sinovac Biotech Ltd. on this page are 1globe Capital LLC (32.3%), Saif Partners Iv L.P. (15%) and Weidong Yin (8.85%).
When did 1globe Capital LLC buy into Sinovac Biotech Ltd.?
The filings give report dates, not purchase dates. The earliest filing from 1globe Capital LLC on this page is the Schedule 13D/A, filed 2025-07-01, reporting 32.3%; its latest, Schedule 13D/A filed 2025-09-12, reports 32.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sinovac Biotech Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sinovac Biotech Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sinovac Biotech Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Sinovac Biotech Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 18,515,315 shares (25.8% of shares outstanding), held indirectly through By 1Globe Capital LLC, CDH Utopia Limited and the others (Form 3, 2026-04-17).
- , a director: 10,780,820 shares (15.0% of shares outstanding), held indirectly through By SAIF Partners IV L.P. (Form 3, 2026-03-18).
- , the chief executive and a director: 6,359,500 shares (8.8% of shares outstanding) (Form 3, 2026-03-18).
- , a director: 5,903,000 shares (8.2% of shares outstanding), held indirectly through By Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P. (Form 3, 2026-03-18).
- , the chief financial officer: 355,000 shares (0.49% of shares outstanding) (Form 3, 2026-03-18).
Shares outstanding: 71,860,702 as of 2025-12-31, from the company's latest SEC cover page.
How much has Sinovac Biotech Ltd. raised?
No fundraising or offering filing from Sinovac Biotech Ltd. is on file with us.
Keep reading
More on Sinovac Biotech Ltd. and the records around it.
Sinovac Biotech Ltd. elsewhere on the record
- 5%+ stake filings Dec 2025
Companies that share a holder
- 1Globe Capital LLC also filed stake reports on 1 other company: Crescent Biopharma, Inc. (Oct 2025)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sinovac-biotech